Our observation, that elevated baseline CXCR4 expression in CTCs (≥7% CXCR4+ CTCs) is prognostic of worse PFS in ED-SCLC, whereas CXCR4 overexpression in tumor is not, has several possible explanations beyond study design. The gene discussed is CXCR4; the disease is small cell lung carcinoma.